
Pat Frenchick
Chief Scientific Officer
Patrick (Pat) Frenchick joined Adjuvance as Chief Scientific Officer in April 2020. Dr. Frenchick
has more than 30 years of experience in the development of new therapeutic technologies, from
discovery through initiation of clinical trials. His focus has been vaccines, adjuvants and
formulations, including work with saponins, MPL, cytokines, other chemical adjuvants and
formulations to reduce side effects and access optional routes of vaccine delivery. He has also
worked in senior positions in the acquisition of technologies, strategic planning, and portfolio
management in the US and in Europe. Previously Pat has held positions as Senior VP
Research and Development at Clear Path vaccines, VP Operations and Clinical Operations
CytImmune Sciences and VP Development Combinature Biopharma. Dr. Frenchick received
his B.S. in Biochemistry and PhD in Immunology from the University of Minnesota, was a NIH
Postdoctoral Fellow in Virology at Baylor College of Medicine and has an MBA from Queen’s
University (Kingston, ON, Canada). He is also a US Patent Agent.